Pradaxa MDL Continues To Grow

The Pradaxa Multi District Litigation (MDL)—approved by the US Judicial Panel on Multidistrict Litigation (JPML) recently—has now grown to 78 cases in 19 jurisdictions.

Pradaxa is a blood-thinning medication manufactured by Boehringer Ingelheim Pharmaceuticals that is used for the prevention of strokes, typically in patients with atrial fibrillation or irregular heartbeat.

The MDL, assigned to U.S. Chief Judge David Herndon, is a compilation of cases claiming that the drug maker failed to warn patients that Pradaxa could cause serious and possibly fatal bleeding and that the company lacked a reversal agent to counteract the drug’s anticoagulation effects, according to the Madison Record.

In his first case management order, the judge indicated that the litigation should move quickly and efficiently so that the matter is resolved in a just manner.

The judge promised that the defendants, who "clearly intend to vigorously defend against the allegations made, doctors who make prescription decisions, and the public as a whole will benefit from a quick resolution of the matter," according to the Madison Record.

The trials for the first cases are likely to begin in 18 to 24 months from the time the scheduling order is set.

If you or a loved one has been harmed by Pradaxa or another dangerous drug, contact Sokolove Law today for a free legal consultation and to find out if a dangerous drug lawyer may be able to help you.

Tags: